Pharmaceutical - Alexion Pharmaceuticals

Filter

Current filters:

Alexion Pharmaceuticals

Popular Filters

Alexion inks deal with Moderna for rare diseases; “deal of the year” say analysts

Alexion inks deal with Moderna for rare diseases; “deal of the year” say analysts

15-01-2014

US drugmaker Alexion Pharmaceuticals has signed an exclusive strategic agreement with privately-held…

Alexion PharmaceuticalsLicensingModerna TherapeuticsPharmaceuticalRare diseases

Citing “unreasonable price,” New Zealand declines eculizumab funding

Citing “unreasonable price,” New Zealand declines eculizumab funding

13-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC has declined the funding application for eculizumab…

Alexion PharmaceuticalsAsia-PacificeculizumabGlaxoSmithKlineHematologyNew ZealandPharmaceuticalPricingRare diseasesRevoladeSoliris

Alexion's Soliris gets approval in Japan for rare disorder

13-09-2013

The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Soliris (eculizumab) from US drugmaker…

Alexion PharmaceuticalsAsia-PacificPharmaceuticalRare diseasesRegulationSoliris

Deal between Ensemble and Alexion will target ultra-rare disorders

18-07-2013

USA-based drug discovery firm Ensemble Therapeutics has announced the initiation of a drug discovery…

Alexion PharmaceuticalsBiotechnologyEnsemble TherapeuticsNorth AmericaPharmaceuticalRare diseasesResearch

Orphan status for Alexion's Solaris

16-07-2013

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says that Soliris (eculizumab), the company's first-in-class…

Alexion PharmaceuticalsBiotechnologyEuropeNeurologicalPharmaceuticalRare diseasesRegulationSolaris

New Zealand declines Alexion's funding application for Solaris

21-05-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to decline the…

Alexion PharmaceuticalsAsia-PacificHealthcarePharmaceuticalPricingRare diseasesSolaris

Alexion tells shareholders to reject TRC's unsolicited mini-tender offer

07-02-2013

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) says it has been notified of an , unsolicited "mini-tender"…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceutical

ASN meeting highlights Otsuka's tolvaptan' Alexion's Solaris and Roche's aleglitazar research

05-11-2012

Japan's Otsuka Pharmaceutical (TYO: 4768) that the clinical trial results for tolvaptan, an investigational…

aleglitazarAlexion PharmaceuticalsNephrology and HepatologyOtsukaPharmaceuticalResearchRocheSolaristolvaptan

EMA orphan drug committee makes 16 recommendations at May meeting

28-05-2012

The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a total of 16…

Alexion PharmaceuticalsBiotechnologyeculizumabEuropePharmaceuticalRare diseasesRegulation

Alexion to buy Enobia Pharma for potential $1 billion

30-12-2011

US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has reached agreement to acquire privately held Canadian…

Alexion Pharmaceuticalsasfotase alfaEnobia PharmaMergers & AcquisitionsPharmaceuticalRare diseases

Company Spotlight

ImmunoGen

ImmunoGen

Back to top